You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華仁藥業(300110.SZ):上半年預盈6615.77萬元至8085.94萬元 同比變動-10%至10%
格隆匯 07-07 18:03

格隆匯7月7日丨華仁藥業(300110.SZ)披露2022年半年度業績預吿,預計2022年1-6月實現歸屬於上市公司股東的淨利潤6615.77萬元至8085.94萬元,同比變動-10%10%;扣除非經常性損益後的淨利潤為5944.73萬元7265.79萬元,同比變動-10%10%。業績變動原因説明:

1、報吿期內,公司積極克服疫情和宏觀環境帶來的困難和影響,確保生產經營的正常運行,保障產品穩定供應。同時,不斷加強核心產品、核心團隊、核心客户建設,積極參與國家、省級、地市級三級集採,加強市場準入,實施精細化招商,穩定存量的同時積極開拓增量客户,實現公司自產藥品銷售量和銷售收入穩中有升。

2、受疫情和宏觀環境影響,上半年能源、物流成本不斷增加,壓縮了公司的利潤空間。

3、2021年8月,公司通過全資子公司西安曲江華仁藥業有限公司收購西安恆聚星醫藥有限公司100%股權,間接持有安徽恆星製藥有限公司100%股權,並於2021年8月起納入合併報表,與上年同期相比,報吿期內貢獻了部分利潤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account